Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo

INDIANAPOLIS and ANAHEIM, Calif.; July 19, 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California. Attendees will have the opportunity to experience firsthand Roche's latest advancements in lab automation, core lab systems, and molecular and point-of-care solutions, as well as learn more about advancements in breakthrough high-medical-value diagnostic and digital solutions that are transforming patient care. 

Roche will feature its newest innovations including the cobas® 5800, a compact, fully-automated molecular PCR-testing solution with a comprehensive menu of assays, and cobas® pure integrated solutions, which combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. The new cobas® connection modules (CCM vertical*), a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules, will also be highlighted, along with Roche’s vision for the transformation of mass spectrometry testing. These systems can provide healthcare communities with the future benefit of an extended diagnostic platform offering clinical chemistry, molecular diagnostics, immunoassays and mass spectrometry. The cobas® pulse system*, a next generation point-of-care blood glucose management device and digital platform, will also be available for attendees to experience. Finally, Roche will introduce its navify® digital solutions, an end-to-end integrated, secure and cohesive solution that delivers data-driven insights to enhance efficiency across the healthcare ecosystem.


We are excited to showcase our integrated solutions that simplify laboratory operations and provide clinicians with reliable and timely test results,” said Brad Moore, president and CEO of Roche Diagnostics North America. “Our collaboration with laboratory professionals is critical because they are supporting clinical decisions that can improve patient care, which is why we remain unwavering in our commitment to science, simplicity and partnership.


Roche will also present seven Roche Idea Lab segments in booth 2201, where experts will discuss topics such as mass spectrometry, digital solutions, point of care, and the use of high-medical-value assays when treating Alzheimer’s disease and heart failure. Scientific industry workshops will include “The future of mass spectrometry from Roche,” “The future of diagnostics in the evolving Alzheimer’s disease care landscape” and “Precision medicine from a pathologist’s perspective in China.” For more information about Roche’s participation at AACC 2023 and Roche Idea Lab programming, visit

Tuesday, July 25

Tuesday, July 25

10:30 – 11 a.m. PST
  • Speakers: 
    • Tobias Franz, international business leader, mass spectrometry, Roche Diagnostics 
    • Benjamin Lilienfeld, lifecycle leader, SWA systems, Roche Diagnostics
  • Moderator: Claire Rhodes, product manager, low volume and specialty analyzers, Core Lab, Roche Diagnostics
1:30 – 2 p.m. PST
  • Speaker: Jina Forys, director of acute laboratories, M Health Fairview
  • Moderator: Amanda Bos, corporate accounts director, Roche Diagnostics
2:30 – 3 p.m. PST
  • Speaker: M. Laura Parnas, Ph.D., disease area network lead, Roche Diagnostics
  • Moderator: Maria-Magdalena Patru, M.D., Ph.D., scientific partner, neurology, Roche Diagnostics
3:30 – 4 p.m. PST
  • Speaker: Nam K. Tran, Ph.D., UC Davis
  • Moderator: David Cowlin, U.S. marketing manager - Core Lab IT, Roche Diagnostics
Wednesday, July 26

Wednesday, July 26

10:30 – 11 a.m. PST            
  • Speakers:
    • Ambarish Pandey, M.D., MSCS, FAHA, associate professor of cardiology, Department of Internal Medicine, UT Southwestern Medical Center
    • Robert Christenson, Ph.D., DABCC, FAACC, FACC, professor of pathology and of medical and research technology, University of Maryland School of Medicine
  • Moderator: Dagmar Schumacher, Ph.D., scientific partner, cardiometabolism, Roche Diagnostics
2:30 – 3 p.m. PST
  • Speakers: 
    • Payal Patel, M.D., Intermountain Health
    • Omai Garner, Ph.D., D(ABMM), UCLA
  • Moderator: Alesia McKeown, Ph.D., scientific partner, infectious diseases, Roche Diagnostics
3 – 3:30 p.m. PST
  • Speaker: Sarah Wheeler, Ph.D., UPMC
  • Moderator: Kwaku D. Tawiah, Ph.D., scientific partner, infectious disease, Roche Diagnostics
About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.


*Not currently for sale in the United States.

For further information

Roche Diagnostics U.S. Media Relations

[email protected]



Gina Goodenough


[email protected]



Jen Dial


[email protected]